CB Therapeutics Continues to Advance its Intellectual Property Portfolio with New Patent Awards
SAN DIEGO--(BUSINESS WIRE)--Nov 14, 2019--
CB Therapeutics is a leading synthetic biotechnology company focused on the research and development of cellular agriculture for the production of high-value molecules, compounds and rare ingredients. CB Therapeutics has been awarded a patent on Oct 10, 2019, titled “Isolated codon optimized Nucleic Acids”. This patent covers inventions related to the optimization of the entire biosynthetic cannabinoid pathway, from precursors to the final cannabinoid product.
“We are excited about this patent award, as it covers the fundamentals of using genetic engineering tools for the production of cannabinoids in many different types of hosts and systems, ranging from bacteria, yeast, to cell-free expression systems,” said Dr. Jacob Vogan, CSO of CB Therapeutics.
The patent allows CB Therapeutics to effectively use genetic engineering techniques and tools to enable high yield production of cannabinoids and their analogs while supporting the ability to integrate their platform into many hosts and systems seamlessly, with specific protocols for such techniques. The patent will also allow for the precise control of individual levels of cannabinoids and terpenes in the final product, ensuring the highest levels of quality and specificity for the needs of customers’ developing cannabinoid products and therapeutics. This cellular agriculture or fermentative biosynthesis technology replaces unsustainable agricultural techniques to grow hemp or cannabis and inefficient extraction processes to isolate CBD and other rare cannabinoids.
“Our team of talented scientists and engineers are dedicated to developing new methods and systems to advance synthetic genomics and bio-engineering. Their serious dedication to innovative science is beginning to pay significant dividends for the advancement of our platform. This has resulted in a rapidly growing IP portfolio as we continue to file patent applications directed towards product recovery, optimization techniques to increase yields and other methods used to improve the overall production process,” said Sher Butt, CEO of CB Therapeutics.
About CB Therapeutics
CB Therapeutics is currently producing high value molecules, compounds and rare ingredients from simple sugars utilizing yeast and the process of fermentation. CB Therapeutics’ expertise in synthetic genomics and bio-engineering has significantly advanced its proprietary production platform of yeasts, enzymes and production processes. After more than four years of research and development, the CB Therapeutics team is able to produce a broad range of phytochemicals faster, utilizing fewer resources, at greater yields and with more purity, consistency and efficiency than competing platforms. A 7000+ sf fully-licensed commercial batch facility in San Diego County, California includes research labs, offices and a production facility for laboratory scale and pilot production runs and is equipped with a suite of bench-top and large-scale fermenters for multiple biosynthetic production applications.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191114005081/en/
CONTACT: Sher Ali Butt
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE AGRICULTURE BIOTECHNOLOGY RESEARCH NATURAL RESOURCES ALTERNATIVE MEDICINE HEALTH
SOURCE: CB Therapeutics
Copyright Business Wire 2019.
PUB: 11/14/2019 10:00 AM/DISC: 11/14/2019 10:01 AM